MCHC (Microcrystalline Hydroxyapatite Concentrate)
1. Identity: Names, Source, and Forms
Chemical and Common Names
Microcrystalline Hydroxyapatite Concentrate (MCHC) is a bioactive compound derived primarily from bovine bone, composed of highly absorbable calcium, phosphorus, collagenous proteins, and trace minerals. It is also encountered in the scientific and regulatory literature under several related designations, including microcrystalline hydroxyapatite compound (MCHC), microcrystalline calcium hydroxyapatite (MCHA or MCH), and — particularly in European clinical literature — ossein-hydroxyapatite complex (OHC). Commercial brand names used in research include Ossopan and Osteogenon.
Hydroxyapatite, sometimes referred to as durapatite, is a calcium phosphate/hydroxide mineral that occurs naturally in "phosphate rock" and is present in as much as 70 wt% of human bone. Although the formula for hydroxyapatite is usually expressed as Ca₅(PO₄)₃OH, it is sometimes given as Ca₁₀(PO₄)₆OH₂ or 3Ca₂(PO₄)₂·CaOH₂ to indicate that its crystal unit cell consists of two formula weights. Hydroxyapatite is a calcium phosphate with the molecular formula Ca₅(PO₄)₃(OH), containing almost 40% calcium and around 18% phosphorus, which means there is a ratio of calcium to phosphorus of 1.67. HA has a typical apatite lattice structure and forms crystals inside the body.
Ossein-hydroxyapatite and microcrystalline hydroxyapatite, both derived from natural sources such as bovine bone, contain approximately 20–25% elemental calcium by weight. Ossein-hydroxyapatite is a composite of collagen protein (ossein) and hydroxyapatite. OHC is composed of ossein, the protein that forms the organic matrix of vertebrate bone, and hydroxyapatite (Ca₅[PO₄]₃OH), the principal bone salt of vertebrate bone; in OHC, these two substances are found in the same physiological proportions as in vertebrate bone.
Natural Source
Microcrystalline hydroxyapatite is extracted from bovine bone and contains the mineral matrix found in human bones. The source material is typically the long bones or whole bones of cattle, and sourcing from young, pasture-raised animals is a quality consideration recognized within the industry. MCH, derived from bovine bone, contains Ca and phosphate in the form of hydroxyapatite, as well as collagenous and non-collagenous bone proteins.
Hydroxyapatite crystals, as a bioactive ceramic, account for 65% to 70% of its weight in human bone. Furthermore, the architecture of the bone comprises type-I collagen as the organic component and hydroxyapatite as an inorganic component.
Common Forms and Preparations
MCHC is commercially available as tablets, capsules, and powder. In early clinical trials, some patients expressed dissatisfaction with the palatability of the powder formulation and were changed to an equivalent dose of tablets, after which all successfully completed the trial. Tablets, vegetarian capsules, and compounded powders remain the most common dietary supplement forms available today.
2. Traditional and Historical Use
Historically, indigenous cultures and traditional healing systems occasionally used preparations derived from animal bones, recognizing their nutritional and restorative properties. Bone broths and similar preparations, which inherently contained natural hydroxyapatite along with collagen, minerals, and proteins, have been consumed globally throughout human history to support health, recovery from illness, and skeletal strength.
As a defined, concentrated dietary supplement, MCHC does not have a long independent ethnobotanical or traditional medicine history in the way that plant-derived ingredients do. Rather, it represents a 20th-century scientific isolate of a substance that has long been consumed indirectly through food. The specific scientific extraction and medical usage of microcrystalline hydroxyapatite began gaining momentum in the 1960s and 1970s, driven by research into novel, bioavailable forms of calcium supplementation. During this period, researchers recognized the potential advantages of a bone-derived calcium source containing intact mineral-protein complexes.
MCHC has a long history of use in Europe for bone health, and most major guidelines for osteoporosis management prioritize well-studied interventions over MCHC as a primary therapy. The product was studied extensively in European clinical settings from the early 1980s onward, particularly in the United Kingdom and Spain, under brand names such as Ossopan (Pierre Fabre Medicament).
3. Key Constituents and Active Compounds
MCHC is distinguished from simple calcium salts by providing the full biochemical matrix of bone tissue, not merely elemental calcium. Its principal constituents include:
- Calcium and phosphate as hydroxyapatite: Among micronutrients, calcium (Ca) and inorganic phosphate (P) are the two main constituents of hydroxyapatite, the bone mineral that strengthens the mechanical resistance of the organic matrix. Bone contains about 99% and 80% of the body's entire supply of Ca and P, respectively.
- Type I collagen (ossein): Type I collagen is the most abundant protein in the body and the predominant collagen found in adult bone. As the building block for all the body's major systems, collagen builds and supports bone matrix and repairs connective tissue. Specialized analysis confirms the presence of 18 separate amino acids, including hydroxyproline and hydroxylysine, which are specific to collagen and especially important for collagen production.
- Osteocalcin: Osteocalcin and collagen type I as components of ossein regulate osteoblast activity and bone remodeling, and are the basis for the formation of matrix and for its mineralization.
- Growth factors: The complex contains growth factors (insulin-like growth factor-1 and -2, transforming growth factor-beta), which stimulate the proliferation and differentiation of preosteogenic forming cells and regenerate specific tissue structures.
- Glycosaminoglycans: Unlike isolated calcium salts, MCHC provides the complete bone matrix: calcium phosphate in hydroxyapatite crystal structure, naturally occurring bone protein fractions, collagen peptides, glycosaminoglycans (including chondroitin sulphate), and naturally occurring bone growth factors.
- Trace minerals: The ossein-hydroxyapatite complex is a microcrystalline form of calcium which provides a number of additional minerals (magnesium, phosphorus, potassium, zinc), and proteins (osteocalcin, type I collagen, type I insulin growth factor I and II, transforming growth factor beta) associated with bone metabolism.
A quantified compositional profile has been documented for one well-studied OHC tablet formulation: an 830 mg tablet of OHC (Osteopor®, Ossopan®, Osteogenon®; Pierre Fabre Medicament, Castres, France) contains 178 mg of calcium, 82 mg of phosphorus and a range of bone metabolism proteins and other factors (osteocalcin 5.8 µg, type I collagen 216 mg, insulin-like growth factor I [IGF-I] 168 ng, IGF-II 84 ng and transforming growth factor β [TGF-β] 21 ng).
A separate double-blind RCT documented another OHC formulation providing: hydroxyapatite, collagens and non-collagenous proteins/peptides containing insulin-like growth factor I (IGF-I; 1341 ng), insulin-like growth factor II (IGF-II; 670 ng), transforming growth factor beta (TGF-β; 166 ng) and osteocalcin (47 µg) — illustrating that growth factor concentrations can vary between preparations.
4. Established Mechanisms of Action
4.1 Calcium and Phosphate Delivery
Mechanistically, MCHC provides a bioavailable source of calcium and phosphate, mimicking the natural matrix of bone, which may enhance absorption and utilization. A key proposed advantage over conventional calcium salts is that MCHC is absorbed more slowly, producing a smaller acute rise in serum calcium. The improved material supports bone mineralization without causing any spiking of blood calcium levels because the calcium is released and absorbed over a relatively long time following ingestion.
This pharmacokinetic difference was confirmed clinically: MCH increased ionized Ca concentrations less than the citrate-carbonate dose; however, it raised the concentrations of phosphate and the Ca-phosphate product. The citrate-carbonate and MCH doses produced comparable decreases in bone resorption (measured as serum C-telopeptide, CTX) over 8 h and bone turnover (CTX and procollagen type-I N-terminal propeptide) at 3 months.
A significant increase in plasma calcium levels associated with a similar increase in phosphate levels was documented during MCHC treatment, and the calcium × phosphate product therefore increased, producing the necessary biochemical environment for bone remineralization.
4.2 Osteoblast Stimulation via Growth Factors and Proteins
The complex contains growth factors (insulin-like growth factor-1 and -2, transforming growth factor-beta), which stimulate the proliferation and differentiation of preosteogenic forming cells and regenerate specific tissue structures. Osteocalcin and collagen type I as components of ossein regulate osteoblast activity and bone remodeling and are the basis for the formation of matrix and for its mineralization. These organic components are proposed to explain why OHC/MCHC shows greater efficacy than simple calcium salts in several studies.
The proposed mechanisms include the bioavailability of calcium and phosphorus, as well as the presence of bone matrix proteins that may enhance bone remodeling.
4.3 Suppression of Parathyroid Over-Activity
In the corticosteroid-treated patient populations studied, biochemical investigations were suggestive of a reduction in parathyroid over-activity in the MCHC group compared to controls, suggesting a secondary mechanism involving modulation of the parathyroid hormone axis and calcium homeostasis.
4.4 Dental Remineralization
For oral applications, hydroxyapatite's mechanism is distinct. Lin et al. (2014) discovered a significant inhibition of future demineralization under acidic conditions after HAP application due to the formation of a protective HAP layer over the prism-prism sheath interfaces, where enamel dissolution usually is initiated. Hannig and Hannig (2010) noted that physiological tooth wear constantly releases HAP particles into the oral environment, which may subsequently interfere with de- and remineralization processes as well as with the metabolism of the oral microbiota at the tooth-bacterial biofilm interface.
5. Scientific Evidence by Area of Use
5.1 Osteoporosis and Bone Mineral Density
Evidence strength: Moderate — multiple small-to-medium RCTs and one meta-analysis, consistent direction of effect, but trials generally small, not all blinded, and many conducted in the 1980s–2000s.
The best-summarized evidence comes from a meta-analysis published using data from MEDLINE (1966–2008), EMBASE (1974–2008), and the Cochrane Controlled Clinical Trials Register. There is increasing evidence to suggest that ossein-hydroxyapatite complex (OHC) is more effective than calcium supplements in maintaining bone mass. The aim of this meta-analysis was to determine whether OHC has a different clinical effect on bone mineral density (BMD) compared with calcium carbonate (CC), and a meta-analysis of randomized controlled clinical trials was carried out to evaluate the efficacy of OHC versus CC on trabecular BMD. Of the 18 controlled trials initially identified, 6 were included in the meta-analysis. There was no significant heterogeneity among the included trials. The percent change in BMD significantly favored the OHC group (1.02% [95% CI, 0.63–1.41], P < 0.00001). These results were confirmed in the sensitivity analysis. OHC is significantly more effective in preventing bone loss than CC.
This meta-analysis was quality-assessed and indexed in the NCBI Database of Abstracts of Reviews of Effects (DARE). A review covering clinical trial data up to December 2013 confirmed: different randomized clinical trials and meta-analyses suggest that OHC is more effective than calcium supplements in maintaining bone mass in postmenopausal women and in different conditions related to secondary bone loss.
One double-blind RCT aimed to evaluate whether OHC is more effective than calcium carbonate (CC) in preventing further bone loss in postmenopausal osteoporosis; 40 osteoporotic patients were monitored for 20 months, randomly assigned to treatment with 1400 mg calcium per day as either OHC or CC. Bone densities were evaluated at intervals of 4 months with high-precision peripheral quantitative computed tomography. After 20 months of treatment, the loss of trabecular bone was 0.8 ± 0.5% in the OHC group and 1.8 ± 0.7% in the CC group.
A few randomized controlled trials found that MCHC supplementation led to a slower rate of bone mineral density (BMD) loss in postmenopausal women, particularly when combined with vitamin D. However, these studies are generally small, of short duration, and sometimes sponsored by supplement manufacturers, limiting the strength of the evidence.
A 2014 RCT from the University of Auckland compared MCH to calcium citrate/carbonate in 100 postmenopausal women (mean age 71 years). The trial randomized 100 women (mean age 71 years) to 1 g/d of Ca as citrate or carbonate (citrate–carbonate), one of two MCH preparations, or a placebo, with blood sampled for 8 hours after the first dose, and after 3 months of daily supplementation. These findings suggest that Ca preparations, in general, produce repeated sustained increases in serum Ca concentrations after ingestion of each dose, and that Ca supplements with smaller effects on serum Ca concentrations may have equivalent efficacy in suppressing bone turnover.
There are no reliable studies to validate the claims made about microcrystalline hydroxyapatite and to compare its efficacy with other forms of calcium supplementation according to Wikipedia's calcium supplement article, reflecting the ongoing limitations of the evidence base. This view aligns with the overall picture: there is insufficient robust evidence to recommend MCHC as a primary or stand-alone treatment for osteoporosis.
5.2 Corticosteroid-Induced Osteoporosis
Evidence strength: Moderate — two published controlled trials in steroid-treated patient populations, with consistent favorable findings, though sample sizes are small.
A controlled clinical trial was carried out in 40 patients at risk of osteoporosis because of long-term treatment with prednisolone (5 to 20 mg/day) to determine the efficacy and tolerance of MCHC when used to prevent the appearance or progression of osteoporosis: 32 patients were treated with 6 to 8 g MCHC for 12 months and 8 served as an untreated control group. The two groups were well matched as regards age, sex and underlying disease; 37 patients (29 MCHC, 8 control) successfully completed the trial. In the MCHC-treated group, there was a dramatic and significant (p less than 0.001) reduction in pain during the trial, almost to the point of its disappearance. Of 19 patients with initial back pain, only 2 still reported any pain at all after 12-months' MCHC treatment. Both mean cortical thickness and mean metacarpal index figures showed small, insignificant decreases during 12-months' MCHC treatment but much more marked decreases in the control group which, despite the small number of patients, came close to being statistically significant.
A second 2-year controlled trial examined MCHC in 36 patients with chronic active hepatitis (CAH) on corticosteroid therapy. A controlled trial was conducted in 36 such patients over a period of 2 years to determine whether MCHC could reduce bone loss or its consequences. Continued reduction in bone mineral content of the radius (photon absorptiometry) was halted in those receiving MCHC and iliac crest bone biopsy showed a non-significant increase in trabecular bone volume. The fall in iliac crest cortical plate thickness was significantly less (P < 0.025) in the MCHC group and the results overall were consistent with a beneficial effect from MCHC in corticosteroid-induced osteoporosis.
5.3 Pain Symptoms in Osteoporosis and Osteopenia
Evidence strength: Preliminary — supported by sub-group analyses and one dedicated placebo-controlled trial, but not the primary endpoint in most bone-density studies.
In patients treated with OHC, mean VAS and VRS pain scores decreased significantly after 5 and 6 months of treatment, indicating a significant analgesic effect. In the CC group, however, changes were minor and non-significant. SF-36 showed significant improvement for OHC on the physical component summary score and no changes for CC. Responses to items assessing emotional and social aspects of quality of life showed only a significant improvement in vitality for OHC. OHC has a significant analgesic effect and improves the physical component of quality of life to a greater extent than CC.
In addition, OHC improves pain symptoms and accelerates fracture consolidation in patients with osteopenia or osteoporosis.
5.4 Osteogenesis Imperfecta (OI)
Evidence strength: Very limited — single small case series; no radiological benefit demonstrated.
Microcrystalline calcium hydroxyapatite compound (MCHC) was given orally together with small doses of dihydrotachysterol (DHT) to a number of patients with osteogenesis imperfecta (OI). Serial calcium and phosphate balances in three patients representing wide variations in severity of OI are presented over periods from eight months to two years. The combination of MCHC and DHT resulted in an immediate positive calcium balance which was maintained throughout the period of assessment in 2 cases. However, no radiological improvement could be demonstrated. Substituting calcium gluconate for MCHC resulted in a reduction of positive balance.
5.5 Dental and Oral Health
Evidence strength: Moderate for remineralization and caries prevention (topical/dentifrice use); evidence is primarily in vitro and in situ with a growing number of clinical trials.
Recently published clinical studies have proven the efficacy of microcrystalline hydroxyapatite (HAP) with respect to caries prevention. HAP is well-known to be biomimetic, or a bionic active ingredient when used in oral care.
A 1-year double-blind RCT specifically assessed a fluoride-free microcrystalline hydroxyapatite toothpaste against a fluoride toothpaste in children's primary dentition. The aim of this trial was to determine whether a toothpaste with microcrystalline hydroxyapatite is not inferior to a fluoride toothpaste in prevention of caries in children. This double-blinded RCT compared two toothpastes regarding the occurrence of caries lesions using the International Caries Detection and Assessment System (ICDAS) within 336 days. The test group used a fluoride-free hydroxyapatite toothpaste three times daily while the control group used a toothpaste with fluoride. 207 children were included in the intention-to-treat analysis; 177 finished the study per protocol. An increase in caries ICDAS ≥ code 1 per tooth was observed in 72.7% of the hydroxyapatite group (n = 88), compared with 74.2% of the fluoride group (n = 89).
The impact of microcrystalline HAP as an ingredient of dentifrices has been positively evaluated in controlled clinical trials regarding dentinal hypersensitivity and parameters of periodontal health.
Unlike fluoride, the accidental swallowing of HAP as a toothpaste ingredient is not associated with any relevant systemic health risks such as fluorosis, as hydroxyapatite is the main inorganic component of all human hard tissues, like teeth and bones.
5.6 Cardiovascular Safety Signal (Serum Calcium Spiking)
Evidence strength: Preliminary mechanistic hypothesis; no definitive clinical harm or benefit from MCHC on cardiovascular outcomes has been established in dedicated trials.
Concerns about conventional calcium supplements and cardiovascular risk have prompted interest in MCH as a potentially safer alternative. Calcium supplements have been associated with increased cardiovascular risk, which may relate to their acute effects on serum calcium concentrations. MCH has previously been shown to have a smaller effect on serum Ca concentrations than conventional Ca supplements 4 hours post-ingestion. MCH could potentially provide a safer form of supplemental Ca to the cardiovascular system than conventional supplements. This hypothesis has not yet been confirmed in dedicated cardiovascular outcome trials.
6. Body Systems and Health Areas
- Skeletal/Musculoskeletal System: MCHC is a compound derived from whole bone, primarily from bovine sources, containing natural calcium, phosphorus, collagen, and other bone matrix proteins. It is used as a dietary supplement to support the structural system, particularly bone health.
- Dental/Oral System: MCHC is a substance derived from bovine bone that contains calcium, phosphorus, protein matrix, and trace minerals, closely resembling the natural composition of human bone and teeth. MCHC has been used as a dietary supplement to support bone and dental health, and hydroxyapatite in dentifrice form has documented remineralization effects on enamel and dentine.
- Endocrine/Hormonal System: Studies in corticosteroid-treated patients suggested MCHC may modulate secondary hyperparathyroidism, influencing the parathyroid hormone-calcium axis.
- Cardiovascular System: Mechanistic studies suggest a smaller acute serum calcium spike compared to calcium carbonate/citrate, with theorized but unproven cardiovascular implications.
- Connective Tissue and Joints: Calcium Microcrystalline Hydroxyapatite (MCHA) is a calcium compound containing minerals in their natural ratios, as well as residues of matrix, proteins, and glycosaminoglycans. MCHA supports bone mineral composition and can potentially reduce the risk of degenerative joint issues.
7. Dosage Forms and Reported Dosages
Dosages reported in published clinical literature vary considerably by formulation and indication:
- 6–8 g MCHC/day for 12 months in a controlled trial of corticosteroid-induced osteoporosis (powder or tablet, as Ossopan). This dose was used in 32 patients treated over 12 months.
- 1400 mg calcium/day as OHC in a 20-month double-blind RCT in postmenopausal osteoporosis. The patients were randomly assigned to one of two groups and treated in a double-masked manner with 1400 mg calcium per day, in the form of either OHC or CC.
- 1 g/day calcium as MCH in a 3-month RCT in postmenopausal women (mean age 71 years), comparing MCH to calcium citrate/carbonate and placebo. This randomized 100 women to 1 g/d of Ca as citrate or carbonate, one of two MCH preparations, or a placebo.
- 830 mg OHC tablet providing 178 mg calcium and 82 mg phosphorus as documented in one compositional analysis. An 830 mg tablet of OHC (Osteopor®, Ossopan®, Osteogenon®; Pierre Fabre Medicament, Castres, France) contains 178 mg of calcium, 82 mg of phosphorus plus the growth factor and protein fraction noted above.
- 2000 mg MCHC providing 500 mg elemental calcium per serving is a commercially documented ratio, as each serving size of 2 vegetarian capsules contains calcium 500 mg from 2000 mg of microcrystalline hydroxyapatite (MCHC), a bioavailable source of calcium derived from whole bone.
For dental use, MCHC is incorporated into toothpastes and mouth rinses at varying concentrations. The RCT in early childhood caries used a fluoride-free hydroxyapatite toothpaste three times daily, though the exact weight percentage was not specified in the abstract.
8. Safety Considerations and Interactions
8.1 General Tolerability
In controlled clinical trials, MCHC has generally been well tolerated. There were no reports of drug-related side-effects in the MCHC-treated patients. Laboratory tests of renal and hepatic function revealed no signs of toxicity during MCHC therapy. No adverse effects were noted in the osteogenesis imperfecta series. OHC demonstrated a lower adverse event rate (<4%) compared to CC, which had adverse rates as high as 18%.
8.2 Heavy Metal Contamination
A key, factually grounded safety concern specific to MCHC is the potential for heavy metal content, arising from the natural propensity of bone tissue to accumulate trace contaminants. Microcrystalline hydroxyapatite, a "second-generation" calcium supplement derived from bovine bone, is claimed by manufacturers to be free of these heavy metals. However, this claim requires independent verification, and California Proposition 65 lead warnings have appeared on some commercial MCHC products. Lead, cadmium, arsenic, and mercury are known to bioaccumulate in bone tissue over the lifetime of the animal.
Safety concerns exist regarding possible contamination and variability in supplement quality. Source and age of the animal are relevant factors: older animals may have higher bone burdens of accumulated heavy metals, making sourcing from young, traceable animals a quality consideration. MCHC is generally recognized as safe when sourced from properly processed bovine bone.
8.3 Bovine Spongiform Encephalopathy (BSE) Risk
Because MCHC is derived from bovine bone, theoretical concerns about transmissible spongiform encephalopathies exist, although regulatory bodies have established protocols for sourcing from certified BSE-free herds (particularly from Australia and New Zealand). Supplement manufacturers commonly specify BSE-free certification as a quality assurance measure.
8.4 Serum Calcium and Phosphate Product
Unlike simple calcium salts, MCHC raises both serum calcium and phosphate. MCH increased ionized Ca concentrations less than the citrate-carbonate dose; however, it raised the concentrations of phosphate and the Ca-phosphate product. While this is consistent with bone remineralization, elevated calcium-phosphate products warrant consideration in individuals with renal impairment, where phosphate handling is already compromised. No clinical adverse events linked to this elevation were reported in the reviewed trials.
8.5 Dietary Supplement Quality Variability
Safety concerns exist regarding possible contamination and variability in supplement quality. Commercial MCHC products vary considerably in their actual protein and growth factor content depending on processing methods, the age of source animals, and storage. The microcrystalline structure may also be disrupted by heat or chemical processing, potentially reducing the bioactive profile relative to research-grade preparations.
8.6 Evidence Limitations Bearing on Safety
While MCHC shows promise, the quantity and quality of evidence are not as extensive as for other interventions such as bisphosphonates or vitamin D. Most published trials are small (n = 36–100), of short duration (3 months to 2 years), and some were conducted without full blinding or placebo control. While there is some scientific rationale and limited clinical evidence for MCHC use in osteoporosis, the quality and quantity of data are not strong, and it should not replace established osteoporosis therapies.
References
Volver